TransCode Therapeutics, Inc. (RNAZ)
| Market Cap | 40.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.97M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $3.39 |
| Previous Close | $3.09 |
| Change ($) | 0.30 |
| Change (%) | 9.71% |
| Day's Open | 3.08 |
| Day's Range | 3.04 - 3.45 |
| Day's Volume | 513,894 |
| 52-Week Range | 2.67 - 7.00 |
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the intell...
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics IPO Pricing Release
Transcode Therapeutics, a preclinical biotech developing RNA-based therapies for cancer, filed on Friday with the SEC to raise up to $30 million in an initial public offering.
TransCode Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About RNAZ
TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our strategy seeks to overcome RNA-based therapeutics delivery challenges by repurposing a particle used extensively in humans for imaging purposes to deliver synthetic RNA molecules (called oligonucleotides) to cancer cells. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving pat... [Read more...]
| Industry Biotechnology | IPO Date Jul 9, 2021 |
| CEO R. Michael Dudley | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol RNAZ |